Binder, Jessica http://orcid.org/0000-0003-2091-3950
Ursu, Oleg http://orcid.org/0000-0003-0596-8339
Bologa, Cristian http://orcid.org/0000-0003-2232-4244
Jiang, Shanya http://orcid.org/0000-0001-6564-0859
Maphis, Nicole http://orcid.org/0000-0003-3833-1027
Dadras, Somayeh
Chisholm, Devon
Weick, Jason http://orcid.org/0000-0003-3135-9860
Myers, Orrin
Kumar, Praveen http://orcid.org/0000-0002-4981-9020
Yang, Jeremy J. http://orcid.org/0000-0002-1476-6192
Bhaskar, Kiran http://orcid.org/0000-0001-6064-8106
Oprea, Tudor I. http://orcid.org/0000-0002-6195-6976
Article History
Received: 6 November 2020
Accepted: 21 January 2022
First Online: 11 February 2022
Competing interests
: T.I.O. has received honoraria or consulted for Abbott, AstraZeneca, Chiron, Genentech, Infinity Pharmaceuticals, Merz Pharmaceuticals, Merck Darmstadt, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, Roche, Roivant Discovery, Sanofi, and Wyeth. He is on the Scientific Advisory Board of ChemDiv Inc. and InSilico Medicine. The remaining authors declare no competing interests.